Key Takeaways:
BridgeBio Pharma Inc. (Nasdaq: BBIO) released new data showing its leading drug, acoramidis, has disease-modifying effects in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and a 34 percent advantage over a key rival’s treatment in reducing hospitalizations.
"By linking TTR variability independently to mortality, we’re seeing a mechanistic signal that may help explain acoramidis’ clinical benefit, providing complementary data to support its use in ATTR-CM,” Senthil Selvaraj, M.D. of Duke University School of Medicine, said in a statement.
The new analysis from the Phase 3 ATTRibute-CM study, presented at the Heart Failure 2026 conference, showed acoramidis significantly reduced serum transthyretin (sTTR) variability over time compared to a placebo (p<0.001), a measure independently associated with a lower risk of death. Furthermore, a matching-adjusted indirect comparison against tafamidis, a rival drug, showed a statistically significant 34% reduction in cardiovascular hospitalizations with a favorable mortality trend.
The positive data reinforces the drug's profile as it begins to enter new markets. While BridgeBio shares have fallen about 11% year-to-date, they are up 93.5% over the past year. Analysts have a consensus price target of approximately US$101 for the stock, which closed recently at US$67.45, suggesting a significant potential upside if the company executes on its commercial strategy.
Marketed as Attruby in the U.S. and BEYONTTRA in the European Union and Japan, acoramidis recently gained regulatory approval in Brazil, one of Latin America's largest pharmaceutical markets. Commercialization there is expected to begin later in 2026, adding a new revenue stream. The company reported revenues of $194.52 million for the quarter ended March 2026, beating consensus estimates, though it missed on earnings per share.
The strong clinical data helps de-risk the asset and strengthens its competitive position against established therapies. Investors will be watching for the initial sales data from the Brazil launch and any further data presentations at upcoming medical meetings to gauge the drug's growth trajectory.
This article is for informational purposes only and does not constitute investment advice.
